Patients’ demographics and clinical characteristics
| . | All . | Responsive . | Resistant . | Progressed . |
|---|---|---|---|---|
| No. of patients (%) | 100 (100) | 74 (74) | 18 (18) | 8 (8) |
| Age median (range), y | 55 (19-80) | 56 (19-80) | 55 (31-77) | 50.5 (20-67) |
| Sex, male/female (%) | 66/34 (66:34) | 49/25 (66:34) | 11/7 (61:39) | 6/2 (75:25) |
| Disease stage, CP/AP/BC (%) | 94/4/2 (94:4:2) | 72/2/0 (97:3:0) | 18/0/0 (100:0:0) | 4/2/2 (50:25:25) |
| WBC counts at diagnosis median (range), ×109/L | 99 (9.3-520) | 74 (9.3-520) | 139 (19-327) | 107 (12-196) |
| Hb at diagnosis median (range), g/L | 112 (55-175) | 115 (55-175) | 97 (63-156) | 99 (61-142) |
| Platelet at diagnosis median (range), ×109/L | 503 (96-2990) | 506 (108-2990) | 617 (96-1599) | 282 (127-507) |
| Peripheral blasts at diagnosis median (range), % | 1 (0-16) | 1 (0-10) | 1 (0-9) | 3 (0-16) |
| Additional cytogenetic abnormalities at diagnosis besides Ph chromosome, present/absent (% present) | 4/96 (4) | 1/72 (1) | 2/17 (12) | 1/7 (14) |
| Sokal risk group at diagnosis, low/intermediate/high/unknown (%) | 28/39/31/2 (28:39:31:2) | 24/28/21/1 (32:38:28:1) | 2/9/6/1 (11:50:33:6) | 2/4/4/0 (25:25:50:0) |
| Subtype of TKI therapy, imatinib/2GTKI (%) | 78/22 (78:22) | 56/18 (76:24) | 16/2 (89:11) | 6/2 (75:25) |
| Follow-up duration after TKI therapy median (range), mo | 55 (3-157) | 54 (3-105) | 81 (8-157) | 39 (5-145) |
| Interval between initial sampling at diagnosis and follow-up sampling median (range), mo | 12.5 (3-63) | 12.5 (3-37) | 11.5 (6-63) | 6.5 (3-37) |
| . | All . | Responsive . | Resistant . | Progressed . |
|---|---|---|---|---|
| No. of patients (%) | 100 (100) | 74 (74) | 18 (18) | 8 (8) |
| Age median (range), y | 55 (19-80) | 56 (19-80) | 55 (31-77) | 50.5 (20-67) |
| Sex, male/female (%) | 66/34 (66:34) | 49/25 (66:34) | 11/7 (61:39) | 6/2 (75:25) |
| Disease stage, CP/AP/BC (%) | 94/4/2 (94:4:2) | 72/2/0 (97:3:0) | 18/0/0 (100:0:0) | 4/2/2 (50:25:25) |
| WBC counts at diagnosis median (range), ×109/L | 99 (9.3-520) | 74 (9.3-520) | 139 (19-327) | 107 (12-196) |
| Hb at diagnosis median (range), g/L | 112 (55-175) | 115 (55-175) | 97 (63-156) | 99 (61-142) |
| Platelet at diagnosis median (range), ×109/L | 503 (96-2990) | 506 (108-2990) | 617 (96-1599) | 282 (127-507) |
| Peripheral blasts at diagnosis median (range), % | 1 (0-16) | 1 (0-10) | 1 (0-9) | 3 (0-16) |
| Additional cytogenetic abnormalities at diagnosis besides Ph chromosome, present/absent (% present) | 4/96 (4) | 1/72 (1) | 2/17 (12) | 1/7 (14) |
| Sokal risk group at diagnosis, low/intermediate/high/unknown (%) | 28/39/31/2 (28:39:31:2) | 24/28/21/1 (32:38:28:1) | 2/9/6/1 (11:50:33:6) | 2/4/4/0 (25:25:50:0) |
| Subtype of TKI therapy, imatinib/2GTKI (%) | 78/22 (78:22) | 56/18 (76:24) | 16/2 (89:11) | 6/2 (75:25) |
| Follow-up duration after TKI therapy median (range), mo | 55 (3-157) | 54 (3-105) | 81 (8-157) | 39 (5-145) |
| Interval between initial sampling at diagnosis and follow-up sampling median (range), mo | 12.5 (3-63) | 12.5 (3-37) | 11.5 (6-63) | 6.5 (3-37) |
2GTKI, second-generation TKI; BC, blastic crisis; CP, chronic phase; F, female; Hb, hemoglobin; M, male; Ph, Philadelphia; WBC, white blood cell.